 CORAL GABLES, Fla., Sept. 10, 2021 GLOBE NEWSWIRE -- Catalyst Pharmaceuticals, Inc. Catalyst Nasdaq: CPRX, a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Catalysts Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer COO, will participate in two upcoming investor conferences: 